vTv Therapeutics Inc (VTVT) Fair Value & Analysis
Healthcare · US · Market cap $136M
vTv Therapeutics Inc
VTVT · US
Fair value as of: Jul 25, 2026
From 3 valuation models · updated today
Share price −14.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $14.00 – $42.72 · fair‑value band $1.67 – $4.12 · the $30.73 price screens above the $3.00 fair value. As of Jul 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
vTv Therapeutics Inc (VTVT) currently trades at $30.73, while our model-based Fair Value estimate is $3.00, implying the stock looks roughly 90.2% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, vTv Therapeutics Inc generated revenue of $36.8M at a net margin of 6.1%. It earns a return on equity of -1.5%. The balance sheet holds a net cash position of $88.9M. Fundamentals as of Jul 25, 2026
Our scenario range runs from $1.67 (bear case) to $4.12 (bull case); at $30.73, the current price sits above that range. The share trades about 30% below its 52-week high and 120% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -90%, VTVT screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 25, 2026. TTM = trailing twelve months.
About the company
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
vTv Therapeutics Inc reported revenue of $0 in FY2025 versus $4.0M in FY2021. Reported net income was −$27.0M in FY2025.
Is VTVT fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$29.70 | HK$26.76 | -10% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,704 | kr 209.21 | -88% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is vTv Therapeutics Inc (VTVT) undervalued?
What is the fair value of VTVT?
What is the quality score of VTVT?
What is the revenue of vTv Therapeutics Inc (VTVT)?
What is the net profit margin of VTVT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full vTv Therapeutics Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.